Botulism differential diagnosis

Jump to navigation Jump to search

Botulism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Botulism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Botulism differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Botulism differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Botulism differential diagnosis

CDC on Botulism differential diagnosis

Botulism differential diagnosis in the news

Blogs on Botulism differential diagnosis

Directions to Hospitals Treating Botulism

Risk calculators and risk factors for Botulism differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Michael Maddaleni, B.S., Keanu Ngo[2]

Overview

Botulism produces an acute, afebrile, symmetric, descending flaccid paralysis that begins with cranial-nerve (oculobulbar) dysfunction in an alert patient with intact sensation. It must be differentiated from other disorders of the neuromuscular junction, peripheral nerve/root, motor neuron, muscle, and brainstem, as well as from neurotoxin exposures that impair cholinergic transmission. In a CDC series of 332 U.S. cases (>12 months of age), the illnesses most often on the treating physician's differential were Guillain-Barré syndrome (GBS) and myasthenia gravis (MG); classic features were common, but "atypical" findings (e.g., paresthesias in 17%, elevated CSF protein in 13%, unilateral or ascending findings in a minority) were also reported, so no single feature excludes the diagnosis.[1][2] Because treatment is time-critical and clinical, differentiation should proceed in parallel with, not before, antitoxin decision-making.

Discriminating features of botulism

The following features, taken together, favor botulism over its mimics:[3][4]

  • Descending course beginning with the eyes/bulbar muscles (diplopia, ptosis, dysarthria, dysphagia), in contrast to the classically ascending pattern of GBS and tick paralysis.
  • Symmetric weakness with preserved sensorium and no true sensory loss (paresthesias may rarely occur).
  • Afebrile presentation (fever suggests a superimposed infection or an alternative diagnosis; it may occur in wound botulism).
  • Autonomic/cholinergic signs: fixed or sluggish dilated pupils (mydriasis), dry mouth, ileus/constipation, urinary retention.
  • Normal CSF (protein usually normal), normal neuroimaging, and a characteristic electrodiagnostic profile (below).

Differential diagnosis in adults and older children

Disorder Weakness pattern Sensory loss Reflexes Pupils/autonomic Fever Key discriminator / confirmatory test
Botulism Descending, symmetric Absent Reduced/absent Mydriasis, dry mouth, ileus No Toxin in serum/stool/food; EDx: low CMAP, incremental response to high-frequency (30–50 Hz) RNS or post-exercise facilitation[5]
Guillain-Barré syndrome (AIDP) Ascending, symmetric Present (distal paresthesias) Absent early Labile dysautonomia No CSF albuminocytologic dissociation (may be delayed 1–2 wk); demyelinating NCS[6][7]
Miller Fisher variant of GBS Ophthalmoplegia, ataxia, areflexia (can mimic bulbar botulism) Variable Absent Usually spared No Anti-GQ1b antibody; ascending peripheral involvement[8]
Myasthenia gravis Fatigable ocular/bulbar/limb, fluctuating Absent Normal Pupils spared No AChR/MuSK antibodies; decrement on low-frequency RNS; edrophonium response[9]
Lambert-Eaton myasthenic syndrome Proximal legs>arms; weakness improves briefly with exertion Absent Reduced (facilitate after exercise) Dry mouth, autonomic No Anti-P/Q-type VGCC antibody; marked (>60–100%) post-exercise facilitation; SCLC screen[10]
Tick paralysis Ascending, symmetric Absent Reduced/absent Mydriasis possible (Ixodes) No Finding and removing the attached tick (scalp, groin); normal CSF[11][12]
Organophosphate/carbamate poisoning Generalized, fasciculations, weakness Absent Variable Miosis, muscarinic excess (SLUDGE), bronchorrhea +/– Cholinergic toxidrome; reduced RBC/plasma cholinesterase; exposure history
Tetrodotoxin / paralytic shellfish poisoning Rapid descending paralysis, perioral paresthesias Paresthesias Variable Autonomic instability No Ingestion history (pufferfish/shellfish); rapid onset (minutes–hours)[13]
Brainstem stroke / Bickerstaff encephalitis Often asymmetric; crossed signs +/– Variable Gaze palsy; altered consciousness (Bickerstaff) No MRI (ischemia/hemorrhage/brainstem lesion); altered sensorium
Poliomyelitis / acute flaccid myelitis Asymmetric, proximal Absent (motor) Reduced +/– Yes (febrile prodrome) Preceding febrile illness; CSF pleocytosis; MRI cord/anterior horn; viral PCR

Detailed test performance and interpretation are covered in Laboratory findings and Other diagnostic studies.

Differential diagnosis in infants

In infant botulism (≈95% of confirmed cases occur before 6 months of age), the most common admitting diagnosis is sepsis; as hypotonia progresses, the differential broadens.[14] Analyses of infants treated with BIG-IV but not confirmed to have botulism ("clinical mimics") identify five recurring categories: spinal muscular atrophy type I, metabolic disorders, other infectious diseases, miscellaneous conditions, and probable (untested) infant botulism.[15]

  • Sepsis/meningoencephalitis — febrile, ill-appearing; positive cultures/CSF.[16]
  • Spinal muscular atrophy type I — longer history of weakness; spares extraocular muscles and sphincters (both characteristically involved in botulism); tongue fasciculations; SMN1 genetic testing.[17]
  • Transient neonatal / congenital myasthenic syndromes — onset in first days of life; maternal MG history (transient form); genetic testing.[18]
  • Metabolic/inborn errors, hypothyroidism — targeted metabolic and endocrine studies.[19]
  • GBS (including Miller Fisher) — rare in infancy, occurs in older children; elevated CSF protein and NCS/EMG distinguish it.[20]

The edrophonium (Tensilon) test is generally not indicated in infants, because congenital MG is excluded by history and de novo autoimmune MG does not occur at this age.[21]

Electrodiagnostic differentiation

Electrodiagnostic testing is the single most useful ancillary study for separating botulism from GBS, MG, and LEMS:[22][23]

  • Botulism: low resting CMAP amplitudes with normal motor conduction velocities and normal sensory studies; post-exercise facilitation and an incremental response to high-frequency (30–50 Hz) RNS — the most distinctive finding. Small, short-duration MUAPs on needle EMG. Facilitation in botulism is typically less pronounced than in LEMS but more persistent (minutes).
  • MG: decrement on low-frequency (2–3 Hz) RNS; normal CMAP at rest; abnormal SFEMG jitter.[24]
  • LEMS: low resting CMAP with marked (>60–100%) post-exercise facilitation and decrement at low-frequency RNS.[25]
  • GBS: demyelinating features (prolonged distal latencies, conduction block, slowed velocities, prolonged/absent F-waves); electrodiagnostic abnormalities may be delayed in the first week.[26]

Caveats: In botulism, incremental responses may be absent early or in severe cases, and both HFRNS and post-exercise facilitation lose sensitivity in the post-acute phase; a normal study does not exclude botulism.[27][28]

Clinically actionable points

  • Use the descending vs. ascending distinction and pupillary/autonomic signs as first-line bedside discriminators; confirm with EDx and toxin testing.[29]
  • Do not delay antitoxin while excluding mimics; empiric treatment on clinical suspicion is standard.[30]
  • Search thoroughly for an attached tick (scalp, groin) in any acute ascending flaccid paralysis—removal is curative and averts unnecessary testing.[31]
  • Clustering of cases of symmetric descending paralysis strongly suggests botulism (or shellfish/toxin exposure) and mandates immediate public-health notification.[32]

References

  1. ↑ Rao AK; Lin NH; Jackson KA; Mody RK; Griffin PM (2017). "Clinical Characteristics and Ancillary Test Results Among Patients With Botulism—United States, 2002-2015". Clinical Infectious Diseases. PMID 29293936.
  2. ↑ Lonati D; Schicchi A; Crevani M; et al. (2020). "Foodborne Botulism: Clinical Diagnosis and Medical Treatment". Toxins. PMID 32784744 Check |pmid= value (help).
  3. ↑ Rao AK; Lin NH; Jackson KA; Mody RK; Griffin PM (2017). "Clinical Characteristics and Ancillary Test Results Among Patients With Botulism—United States, 2002-2015". Clinical Infectious Diseases. PMID 29293936.
  4. ↑ Gayed SMA; Motley MP; Carlson JM; Lupu KS; Mavrogiorgos N (2026). "The Eyes Have It". The New England Journal of Medicine. 394 (10): 1011–1017. doi:10.1056/NEJMcps2508044.
  5. ↑ Morena JM (2026). "Electrodiagnostic Approach to Defects of Neuromuscular Transmission". Muscle & Nerve.
  6. ↑ Shahrizaila N; Lehmann HC; Kuwabara S (2021). "Guillain-Barré Syndrome". Lancet.
  7. ↑ Yuki N; Hartung HP (2012). "Guillain–Barré Syndrome". The New England Journal of Medicine.
  8. ↑ Carrillo-Marquez MA (2016). "Botulism". Pediatrics in Review. 37 (5): 183–192. doi:10.1542/pir.2015-0018.
  9. ↑ Punga AR; Maddison P; Heckmann JM; Guptill JT; Evoli A (2022). "Epidemiology, Diagnostics, and Biomarkers of Autoimmune Neuromuscular Junction Disorders". The Lancet Neurology.
  10. ↑ Gable KL; Massey JM (2015). "Presynaptic Disorders: Lambert-Eaton Myasthenic Syndrome and Botulism". Seminars in Neurology. PMID 26502758.
  11. ↑ García-Moncó JC; Benach JL (2025). "Tick-induced neurological disorders". Journal of Neurology.
  12. ↑ Edlow JA (2024). "Tick Paralysis—A Rare but Important Tick-Borne Disease". JAMA Internal Medicine.
  13. ↑ Gayed SMA; Motley MP; Carlson JM; Lupu KS; Mavrogiorgos N (2026). "The Eyes Have It". The New England Journal of Medicine. 394 (10): 1011–1017. doi:10.1056/NEJMcps2508044.
  14. ↑ Carrillo-Marquez MA (2016). "Botulism". Pediatrics in Review. 37 (5): 183–192. doi:10.1542/pir.2015-0018.
  15. ↑ Khouri JM; Payne JR; Arnon SS (2018). "More Clinical Mimics of Infant Botulism". The Journal of Pediatrics. PMID 29229451.
  16. ↑ Carrillo-Marquez MA (2016). "Botulism". Pediatrics in Review. 37 (5): 183–192. doi:10.1542/pir.2015-0018.
  17. ↑ Carrillo-Marquez MA (2016). "Botulism". Pediatrics in Review. 37 (5): 183–192. doi:10.1542/pir.2015-0018.
  18. ↑ Corrado A; Yoshiba G; Buranosky M; et al. (2022). "A 43-Day-Old Male With Respiratory Distress and Acute-Onset Hypotonia". Pediatrics.
  19. ↑ Khouri JM; Payne JR; Arnon SS (2018). "More Clinical Mimics of Infant Botulism". The Journal of Pediatrics. PMID 29229451.
  20. ↑ Berkwitt A; El Saleeby CM; Murphy SA (2024). "Case 3-2024: An 8-Week-Old Male Infant with Inconsolable Crying and Weakness". The New England Journal of Medicine.
  21. ↑ Carrillo-Marquez MA (2016). "Botulism". Pediatrics in Review. 37 (5): 183–192. doi:10.1542/pir.2015-0018.
  22. ↑ Morena JM (2026). "Electrodiagnostic Approach to Defects of Neuromuscular Transmission". Muscle & Nerve.
  23. ↑ Boccagni C; Prestandrea C; D'Agostino T; et al. (2021). "Neurophysiological patterns of acute and post-acute foodborne botulism". Muscle & Nerve.
  24. ↑ Punga AR; Maddison P; Heckmann JM; Guptill JT; Evoli A (2022). "Epidemiology, Diagnostics, and Biomarkers of Autoimmune Neuromuscular Junction Disorders". The Lancet Neurology.
  25. ↑ Gable KL; Massey JM (2015). "Presynaptic Disorders: Lambert-Eaton Myasthenic Syndrome and Botulism". Seminars in Neurology. PMID 26502758.
  26. ↑ Willison HJ; Jacobs BC; van Doorn PA (2016). "Guillain-Barré Syndrome". Lancet.
  27. ↑ Boccagni C; Prestandrea C; D'Agostino T; et al. (2021). "Neurophysiological patterns of acute and post-acute foodborne botulism". Muscle & Nerve.
  28. ↑ Liu SC; Poon JT; Candee MS (2021). "Clinical Reasoning: A Teenager With Shortness of Breath and Difficulty Walking". Neurology.
  29. ↑ Shahrizaila N; Lehmann HC; Kuwabara S (2021). "Guillain-Barré Syndrome". Lancet.
  30. ↑ Gayed SMA; Motley MP; Carlson JM; Lupu KS; Mavrogiorgos N (2026). "The Eyes Have It". The New England Journal of Medicine. 394 (10): 1011–1017. doi:10.1056/NEJMcps2508044.
  31. ↑ Edlow JA (2024). "Tick Paralysis—A Rare but Important Tick-Borne Disease". JAMA Internal Medicine.
  32. ↑ Gayed SMA; Motley MP; Carlson JM; Lupu KS; Mavrogiorgos N (2026). "The Eyes Have It". The New England Journal of Medicine. 394 (10): 1011–1017. doi:10.1056/NEJMcps2508044.


Template:WikiDoc Sources